Centessa IPO Presentation Deck

MGX292: Status and Competition STATUS & UPCOMING MILESTONES MGX292 is currently in preclinical development Mid-to-late 2022 US IND Filing COMPETITIVE LANDSCAPE 000 MORPHOGEN-IX Sotatercept, a ligand trap with high selectivity for multiple proteins within the TGF-B superfamily: Phase 3 (Acceleron Pharma) KER-012, a protein therapeutic designed to bind to and inhibit the signaling of TGF-B ligands: Preclinical development (Keros Therapeutics) CENTESSA 28

View entire presentation